The selective BCL-2 inhibitor venetoclax has proven strong efficacy in many hematological cancers (ex., chronic lymphocytic lymphoma, acute myeloid leukemia, mantle cell lymphoma), which share its dependency on BCL-2 anti-apoptotic signaling [5,6,7]. Here, BCL2 is linked to mantle cell lymphoma.